Lv5
1440 积分 2022-09-21 加入
Halda Therapeutics
1天前
已完结
Halda emerges from stealth with bifunctional molecules to treat cancer
1天前
已完结
RIPTACs: A groundbreaking approach to drug discovery
1天前
已完结
RIPTACs expand anticancer target space
1天前
已完结
Induced proximity pushes beyond protein degraders, as first RIPTAC moves into the clinic
1天前
已完结
Evaluation of the safety, tolerability, and pharmacokinetics of RO7049389 in healthy Chinese volunteers
2个月前
已完结
Abstract 2306: BLU-222, an investigational, potent, and selective CDK2 inhibitor, demonstrated robust antitumor activity in CCNE1-amplified ovarian cancer models
3个月前
已完结
Abstract ND06: First disclosure of AZD8421, a highly selective CDK2 inhibitor to address resistance to CDK4/6 inhibitors in breast and CCNE1-high cancers
3个月前
已关闭
Discovery of INCB123667, a potent and selective cyclin-dependent kinase 2 (CDK2) inhibitor for the treatment of cyclin E dysregulated cancers
3个月前
已完结
Targeting cyclin-dependent kinase 2 (CDK2) interactions with cyclins and Speedy 1 (Spy1) for cancer and male contraception
3个月前
已完结
皖公网安备34019202002308
